Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 11/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3876908 | 1.00 | CHRM4 (0.46) | CHRM4TP53MAPTALOX15MAPK1 | |
| SCHEMBL2550208 | 1.00 | CHRM4 (0.46) | CHRM4TP53MAPTALOX15MAPK1 | |
| SCHEMBL2247219 | 0.88 | CHRM2 (0.51) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL2549773 | 0.84 | KCNA5 (0.44) | CHRM4MAPTALOX15MAPK1KCNA5 | |
| SCHEMBL2246813 | 0.84 | KCNA5 (0.44) | CHRM4MAPTALOX15MAPK1KCNA5 | |
| SCHEMBL1827654 | 0.80 | PPARA (0.43) | — | |
| SCHEMBL1824528 | 0.79 | KMT2A (0.47) | MAPTSMN1; SMN2CHRM1HTT | |
| SCHEMBL2245212 | 0.76 | GRM5 (0.42) | TP53MAPTALOX15MAPK1SMN1; SMN2 | |
| SCHEMBL13876582 | 0.76 | MAPT (0.41) | MAPTSMN1; SMN2HTT | |
| SCHEMBL2244594 | 0.76 | CA12 (0.46) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008302-B2 | ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | claimed |
| EP-1771421-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | SERONO LAB (CH) | 2009-04-29 | — | — | EP | claimed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | claimed |
| US-8247437-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | disclosed |
| US-8008302-B2 | ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | disclosed |
| EP-1771421-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | SERONO LAB (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | CHRM4 1379/4885TP53 2392/4885MAPT 2854/4885 |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | HCAR2, HNMT, HPGD | CHRM4 1486/4885TP53 2496/4885MAPT 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.